deferoxamine has been researched along with Ischemic Attack, Transient in 14 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study examined the role of deferoxamine (DFX) in brain injury and HT in a rat model of transient focal ischemia with hyperglycemia." | 7.75 | Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. ( Hua, Y; Keep, RF; Xi, G; Xing, Y, 2009) |
| "We examined the effects of subarachnoid hemorrhage (SAH) and treatment with deferoxamine (DFO) or sympathectomy on vascular smooth muscle function, as well as the underlying mechanisms involved, by recording the responses to nor-adrenaline and serotonin in isolated carotid arteries in vitro." | 7.69 | Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage. ( Akgün, M; Göksel, M; Kaya, T; Sarioglu, Y; Solak, O; Utkan, T, 1996) |
| "The role of endothelium-related factors in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage (SAH) has gained interest since the discovery of EDRF and of endothelin-1 (ET-1)." | 7.69 | Effects of deferoxamine and sympathectomy on endothelin-1-induced contraction and acetylcholine-induced relaxation following subarachnoid hemorrhage in carotid artery. ( Akgün, M; Düzcan, E; Sarioğlu, Y; Utkan, NZ; Utkan, T, 1997) |
| "Deferoxamine treatment (50 mg/kg/8 hours) was begun 16 hours before the induction of SAH and continued until the animals were killed by perfusion fixation." | 5.28 | A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. ( Hongo, K; Kassell, NF; Ogawa, H; Tsukahara, T; Vollmer, DG, 1991) |
| " This study examined the role of deferoxamine (DFX) in brain injury and HT in a rat model of transient focal ischemia with hyperglycemia." | 3.75 | Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. ( Hua, Y; Keep, RF; Xi, G; Xing, Y, 2009) |
| "We examined the effects of subarachnoid hemorrhage (SAH) and treatment with deferoxamine (DFO) or sympathectomy on vascular smooth muscle function, as well as the underlying mechanisms involved, by recording the responses to nor-adrenaline and serotonin in isolated carotid arteries in vitro." | 3.69 | Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage. ( Akgün, M; Göksel, M; Kaya, T; Sarioglu, Y; Solak, O; Utkan, T, 1996) |
| "The role of endothelium-related factors in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage (SAH) has gained interest since the discovery of EDRF and of endothelin-1 (ET-1)." | 3.69 | Effects of deferoxamine and sympathectomy on endothelin-1-induced contraction and acetylcholine-induced relaxation following subarachnoid hemorrhage in carotid artery. ( Akgün, M; Düzcan, E; Sarioğlu, Y; Utkan, NZ; Utkan, T, 1997) |
| "Treatment with deferoxamine significantly decreased the size of brain damage (-28%) after ischemia and improved behavioral recovery." | 1.33 | Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. ( Bernaudin, M; Boulouard, M; Chazalviel, L; Freret, T; Mackenzie, ET; Petit, E; Saulnier, R; Schumann-Bard, P; Valable, S, 2006) |
| "With deferoxamine treatment, only a minor increase in latency periods (4." | 1.31 | Evaluation of cerebral vasospasm with transcranial magnetic stimulation: an experimental study. ( Akgün, M; Göksel, HM; Solak, O; Topaktaş, S; Topalkara, K, 2001) |
| "Deferoxamine treatment (50 mg/kg/8 hours) was begun 16 hours before the induction of SAH and continued until the animals were killed by perfusion fixation." | 1.28 | A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. ( Hongo, K; Kassell, NF; Ogawa, H; Tsukahara, T; Vollmer, DG, 1991) |
| " An ischemia control group received NS, whereas experimental groups were given Nx, SOD, APL, or DEF with the same previous dosage schedule." | 1.27 | Experimental pharmacologic cerebroprotection. ( Donovan, DL; Fink, JA; Pigott, JP; Sharp, WV, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xing, Y | 1 |
| Hua, Y | 1 |
| Keep, RF | 1 |
| Xi, G | 1 |
| Freret, T | 1 |
| Valable, S | 1 |
| Chazalviel, L | 1 |
| Saulnier, R | 1 |
| Mackenzie, ET | 1 |
| Petit, E | 1 |
| Bernaudin, M | 1 |
| Boulouard, M | 1 |
| Schumann-Bard, P | 1 |
| Lin, XM | 1 |
| Waller, SB | 1 |
| Dietz, NJ | 1 |
| Vollrath, B | 1 |
| Chan, P | 1 |
| Findlay, M | 1 |
| Cook, D | 1 |
| Luo, Z | 1 |
| Harada, T | 2 |
| London, S | 1 |
| Gajdusek, C | 1 |
| Mayberg, MR | 2 |
| Utkan, T | 2 |
| Sarioglu, Y | 2 |
| Kaya, T | 1 |
| Akgün, M | 3 |
| Göksel, M | 1 |
| Solak, O | 2 |
| Davis, S | 1 |
| Helfaer, MA | 1 |
| Traystman, RJ | 1 |
| Hurn, PD | 1 |
| Düzcan, E | 1 |
| Utkan, NZ | 1 |
| Göksel, HM | 1 |
| Topalkara, K | 1 |
| Topaktaş, S | 1 |
| Prass, K | 1 |
| Ruscher, K | 1 |
| Karsch, M | 1 |
| Isaev, N | 1 |
| Megow, D | 1 |
| Priller, J | 1 |
| Scharff, A | 1 |
| Dirnagl, U | 1 |
| Meisel, A | 1 |
| Vollmer, DG | 1 |
| Hongo, K | 1 |
| Ogawa, H | 1 |
| Tsukahara, T | 1 |
| Kassell, NF | 1 |
| Kumar, K | 1 |
| White, BC | 1 |
| Krause, GS | 1 |
| Indrieri, RJ | 1 |
| Evans, AT | 1 |
| Hoehner, TJ | 1 |
| Garritano, AM | 1 |
| Koestner, A | 1 |
| Pigott, JP | 1 |
| Donovan, DL | 1 |
| Fink, JA | 1 |
| Sharp, WV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Randomized Triple-blind Placebo Controlled Trial of Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival and Neurological Outcome[NCT04009759] | Phase 1 | 240 participants (Anticipated) | Interventional | 2021-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 other studies available for deferoxamine and Ischemic Attack, Transient
| Article | Year |
|---|---|
Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia.
Topics: Animals; Blood-Brain Barrier; Body Water; Brain; Brain Chemistry; Brain Edema; Deferoxamine; Hemoglo | 2009 |
Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat.
Topics: Animals; Behavior, Animal; Brain; Deferoxamine; Hypoxia-Inducible Factor 1, alpha Subunit; Infarctio | 2006 |
Effects of deferoxamine and a diet deficient in vitamin E on isoelectric electroencephalographic responses associated with ischemia by the four vessel occlusion method.
Topics: Animals; Brain; Deferoxamine; Diet; Electroencephalography; Ischemic Attack, Transient; Male; Rats; | 1995 |
Lazaroids and deferoxamine attenuate the intracellular effects of oxyhaemoglobin in vascular smooth muscle.
Topics: Animals; Antioxidants; Calcium; Cell Line; Cell Survival; Chelating Agents; Chromans; Deferoxamine; | 1995 |
Antioxidant and iron-chelating agents in cerebral vasospasm.
Topics: Animals; Antioxidants; Ascorbic Acid; Deferoxamine; Dose-Response Relationship, Drug; Femoral Artery | 1995 |
Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage.
Topics: Animals; Carotid Arteries; Deferoxamine; Disease Models, Animal; Female; Ischemic Attack, Transient; | 1996 |
Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemia in dogs.
Topics: Amino Acids; Animals; Antioxidants; Blood Glucose; Carbon Dioxide; Cerebrovascular Circulation; Defe | 1997 |
Effects of deferoxamine and sympathectomy on endothelin-1-induced contraction and acetylcholine-induced relaxation following subarachnoid hemorrhage in carotid artery.
Topics: Acetylcholine; Animals; Carotid Artery Diseases; Carotid Artery, Common; Deferoxamine; Endothelin-1; | 1997 |
Evaluation of cerebral vasospasm with transcranial magnetic stimulation: an experimental study.
Topics: Animals; Basilar Artery; Blood Pressure; Capillaries; Cerebral Angiography; Deferoxamine; Evoked Pot | 2001 |
Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro.
Topics: Animals; Cell Survival; Cells, Cultured; Cerebral Cortex; Constriction; Cycloheximide; Deferoxamine; | 2002 |
Inhibition of delayed arterial narrowing by the iron-chelating agent deferoxamine.
Topics: Animals; Deferoxamine; Free Radicals; In Vitro Techniques; Iron; Ischemic Attack, Transient; Lipid P | 1992 |
A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage.
Topics: Animals; Basilar Artery; Brain; Deferoxamine; Disease Models, Animal; Iron Chelating Agents; Ischemi | 1991 |
A quantitative morphological assessment of the effect of lidoflazine and deferoxamine therapy on global brain ischaemia.
Topics: Animals; Calcium Channel Blockers; Deferoxamine; Dogs; Drug Therapy, Combination; Iron; Ischemic Att | 1988 |
Experimental pharmacologic cerebroprotection.
Topics: Allopurinol; Animals; Arachidonic Acid; Arachidonic Acids; Brain; Deferoxamine; Ischemic Attack, Tra | 1988 |